Zymeworks (ZYME) has released an update.
Zymeworks Inc., a clinical-stage biotech company, has announced a robust financial position with a cash runway extending into the second half of 2027, buoyed by anticipated regulatory milestone payments. The company has completed significant regulatory filings for its lead drug candidate zanidatamab, including a biologics license application with the FDA for treating biliary tract cancers and is preparing for a Phase 3 clinical trial in HER2-positive breast cancer. Additionally, Zymeworks showcased its research and development prowess with five poster presentations at the recent AACR Annual Meeting, underscoring its commitment to advancing biotherapeutics for cancer treatment.
For further insights into ZYME stock, check out TipRanks’ Stock Analysis page.
